Screener
aTyr Pharma ATYR G&A
G&A at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $6,748 | $15,384 | 14,065 | 27,198 |
| General and administrative | 4,133 | 4,929 | 8,252 | 8,888 |
| Total operating expenses | 10,881 | 20,313 | 22,317 | 36,086 |
| Loss from operations | (10,881) | (20,313) | (22,317) | (36,086) |
| Total other income (expense), net | 571 | 781 | 1,215 | 1,673 |
| Consolidated net loss | (10,310) | (19,532) | (21,102) | (34,413) |
| Net loss attributable to noncontrolling interest in Pangu BioPharma Limited | 1 | 1 | 2 | 2 |
Item 1. Financial Statements
FAQ
- What is aTyr Pharma's G&A?
- aTyr Pharma (ATYR) reported G&A of $4.13M in Q2 2026.
- How has aTyr Pharma's G&A changed year-over-year?
- aTyr Pharma's G&A decreased by 16.1% year-over-year, from $4.93M to $4.13M.
- What is the long-term trend for aTyr Pharma's G&A?
- Over 4 years (2021 to 2025), aTyr Pharma's G&A has grown at a 13.1% compound annual growth rate (CAGR), from $10.75M to $17.6M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about aTyr Pharma's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude